2SEVENTY BIO, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.94 USD | -1.20% |
|
+13.01% | +15.93% |
| May. 08 | Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M | MT |
| May. 08 | Transcript : 2seventy bio, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Presenter SpeechVikram Purohit (Analysts)Okay. Great. Let's go ahead and get started. Welcome,...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patientâs own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
Calendar
2024-06-10
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
5
USD
Average target price
10.5
USD
Spread / Average Target
+110.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.93% | 257M | |
| +33.95% | 50.85B | |
| +0.74% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +10.95% | 26.11B | |
| -21.61% | 19.13B | |
| +9.27% | 13.05B | |
| +27.66% | 12.16B | |
| +23.99% | 12.08B |
- Stock Market
- Equities
- TSVT Stock
- News 2seventy bio, Inc.
- Transcript : 2seventy bio, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 03